Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hangzhou Innoforce and Hibiscus Join to Advance Mayo Clinic’s Cell and Gene Therapies

publication date: Sep 1, 2022

The Mayo Clinic, Hibiscus BioVentures and Hangzhou Innoforce launched Mayflower BioVentures, a cell and gene therapy accelerator that will form companies to develop novel Mayo Clinic technologies through preclinical and early feasibility studies. Although Mayo is a hospital, it has generated a portfolio of next-generation immune system modulators and multiple novel therapeutics in cell and gene therapy. Its Center for Regenerative Biotherapeutics works to advance regenerative technologies from discovery into early phase clinical trials, including collaborations with companies like Hibiscus. Innoforce offers CDMO services to cell and gene therapy companies. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital